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ABSTRACT 
 
Background: Cerebral Autossomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is caused by mutations on the NOTCH3 gene on chromossome 19 
and can be seen as a plemorphic disease with a high variability in clinical manifestations, both between 
diferent families and between relatives from a single family. The main clinical manifestations are early 
onset recurrent subcortical ischemic events, cognitive decline, psychiatric disturbance and migraine 
with aura. Also, it is thought that cardiovascular risk factors (CVRF) migh modulate the disease and 
affect its severity. Diagnosis is made by genetic analysis, but Magnetic Ressonance imaging (MRI) is 
considered a crucial diagnostic tool. Today, there are a large number of reports about CADASIL and is 
known that there are more than 200 mutations associated to CADASIL phenotype. However, the 
geographical distribution of these mutations proved to be variable. In Portugal, 90% of CADASIL 
patients have mutations either on exon 4 or 11. The main aim of this study was to study and identify the 
major clinical manifestations and MRI presentation from a Portuguese sample with known diagnosis of 
CADASIL while trying to describe a phenotype-genotype relation within our sample. 
 
Methods: From a pool of over 1000 patients from 28 portuguese medical centres, we selected 11 
who were followed in S. João Hospital and from whom we were able to collect clinical information by 
a questionnaire created by the Department of Genetics of the Faculty of Medicine. We then screened 
those patients for NOTCH3 mutations. 
 
Results: We found 6 different mutations with 73% or our sample had mutation on exon 4 or 11. The 
most frequent clinical manifestation was Migraine without aura. Other observed manifestations of the 
disease were Depression, Transient ischemic attacks and stroke. From the patients with MRI (4), the 
most frequente findings were áreas of hyperintensity in both the periventricular áreas and centrum 
semiovale. Seven patients had familiar history of symptoms , the most frequente being early onset 
stroke. CVRF were present in 6 patients and dyslipidemia was the most frequent CVRF. 
 
Conclusions: The present study permitted us to conclude that there are very significant similarities 
between portuguese and non-portuguese patients diagnosed with CADASIL despite the different 
clustering regions of the NOTCH3 mutations. We could not create any significant phenotype-genotype 
relation and no significant relation was found between clinical manifestation and familiar history or 
clinical manifestation and CVRF 
  
INTRODUCTION 
Cerebral Autossomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy 
(CADASIL, MIM#125310) is also known by the names of hereditary multi-infarct dementia[1], 
chronic familial vascular encephalopathy[2] or familial subcortical dementia with arteriopathic 
leukoencephalopathy[3]. 
It was possibly first reported by Van Bogaert in 1955, who described two sisters with rapidly 
progressive sub-cortical encephalopathy of Binswanger’s type[4] but only in 1993 Tournier–Lasserve 
et al used the acronym CADASIL for the first time [5]. Later on, in 1996, linkage studies lead to the 
identification of the mutated gene NOTCH3 on chromosome 19 as responsible for the disease [6]. 
CADASIL may be seen as a pleomorphic disease: the dominant manifestations may vary between 
different families and the clinical picture and functional course also differ in individuals of the same 
family[7]. The mean age at onset of symptoms is 45 years and the duration of the disease varies 
between 10 and 40 years [8]. CADASIL is clinically characterized by Transient Ischemic Attacks 
(TIA) and subcortical ischemic strokes with accumulating sensory, motor and cognitive deficits[6,9]. 
Despite the most common clinical findings which include early onset recurrent subcortical ischemic 
events, cognitive decline, psychiatric disturbance and migraine with aura, in certain patients additional 
manifestations such as epilepsy or acute encephalopathy can be found[9-12]. Adding to the general 
symptoms, Adib-Samii et al. reported that cardiovascular risk factors may modulate the disease and 
increase disease severity[13]. 
There are no broadly accepted criteria to diagnose CADASIL however, magnetic resonance imaging 
(MRI) is considered of be crucial for such diagnose since patients with this disease had been reported 
to have imaging abnormalities found in the brain earlier than expected clinically.  Also, in young 
patients who have CADASIL despite being highly characteristic, cerebral abnormalities are limited 
[8,14]. 
Certain specific findings can be observed on cerebral MRI being the frontal lobe the most affected. 
There are also some studies where!higher lesion scores in the temporal white matter were found,!
predominantly, in the temporopolar region as well as in the external capsule and corpus callosum 
which are also characteristic findings, as well as periventricular hyperintensity. Lacunar infarcts, as 
well as microbleeds can also be found, particularly in the basal ganglia, deep white matter, thalamus, 
cerebellum and the mesencephalon [14-18]. 
Despite the exact prevalence of CADASIL being unknown, a study from West Scotland 
demonstrated a prevalence of confirmed CADASIL to be 1.98 per 100 000 adults [19]. According to 
Orphanet, in Europe, the prevalence of CADASIL has been estimated to range between 1 per 50 000 
and 1 per 25 000 (http://www.orpha.net/). 
There has been a gradual increase in the number of reports about patients with CADASIL[4]. 
 
The NOTCH3gene has 33 exons and there are more than 200 different mutations associated with the 
CADASIL phenotype (Human Gene Mutation Database, HGMD; http://www.hgmd.cf.ac.uk, accessed 
March, 2014) 95% of which being missense [20,21]. The described mutations are located in exons 2-24, 
which encode the 34 Epidermal Growth Factor repeats (EGFR) that constitute the extracellular domain 
of the transmembrane receptor encoded by NOTCH3[22]. These mutations are strongly stereotyped and 
either create or destroy a cysteine residue in the EGF-like repeats, leading to an odd number of cysteine 
residues [22]. 
 
While strong clustering of cysteine mutations in EGF-like domains 2–5 (encoded by exons 3 and 4) 
has been described in several western European countries, the exonic distribution of pathogenic 
NOTCH3 mutations shows considerable geographic variation. [23]. In Portugal, approximately 2/3 of 
the NOTCH3 mutations identified in patients with CADASIL mapped to exons 4, 11 and more than 
90% of Portuguese CADASIL patients have one of the mutations described in theses 2 exons[24]. 
To date, several studies have been published concerning the familiar and sporadic spectrum of 
clinical presentation of CADASIL and in most cases it showed to be nearly impossible to establish a 
clear pattern of symptomatic onset of the disease, in both familiar and sporadic cases. Moreover, only a 
few reports in the literature gave evidence of genotype–phenotype correlations in CADASIL [25,26].  
 
Therefore, the prime objectives of our study consisted on studying and identifying the major clinical 
manifestations and MRI imaging presentation in patients from a Portuguese sample with known 
diagnosis of CADASIL and reported mutation involving cysteine residues on NOTCH3 gene, 
describing a phenotype-genotype relation within our sample. 
Also, we aimed to study the presence of other factors that are thought to be important in the natural 
history of CADASIL patients such as the presence of cardiovascular risk factors of the presence of 
familiar history[8,13]. 
 
METHODS 
The Department of Genetics of the Faculty of Medicine of the University of Porto was pioneer in the 
molecular diagnosis of CADASIL in Portugal and since 2004 has a database that now comprises more 
than 1000 patients referred by 28 different Portuguese medical centers. Patients with clinical diagnosis 
of CADASIL gave informed consent and underwent peripheral blood collection for extraction of a 
DNA sample to perform genetic analyses of the NOTCH3 gene, after a formal request made by a 
neurologist or geneticist.  
After consulting this database we enrolled 169 patients in whom a mutation involving a cysteine 
residue had been previously found in the NOTCH3 gene, 115 of these patients were index cases. We 
selected a total of 22 patients followed in S. João Hospital (HSJ). 
From these 22 patients we were able to collect adequate and uniform clinical information of a total of 
11 patients after analyses of a questionnaire, created by the Department of Genetics of the Faculty of 
Medicine, addressed to neurologists and filled by them. [Figure 1] 
Arterial hypertension was defined as systolic blood pressure >140 mmHg, or diastolic blood pressure 
>90 mmHg, diabetes mellitus (DM) was defined according to the World Health Organization (WHO) 
criteria for diagnosis of DM and dyslipidemia were defined as an age adjusted non-fasting cholesterol 
>6 mmol/l. 
Screening for NOTCH3 mutations was performed by DNA sequencing analyses. Genomic DNA was 
extracted from peripheral blood leukocytes using standard protocols.In a sequencial approach 
according to the known mutational hot-spots, exons 2 to 23 of the NOTCH3 gene, including their 
respective exon/intron boundaries, were amplified from genomic DNA samples by the polymerase 
chain reaction (PCR) in a GeneAmp® PCR System thermocycler (GE Applied Biosystems, Foster 
City, CA, U.S.A.) using the primers described in Table1. A 25µl mix was prepared with: 1,0µl DNA 
(100ng/µl); 2,5µl of buffer 10x; 1µl of MgCl2 (25mM); 0,5µl of a dNTP mix at 10mMol (100mM 
dNTP Set, PCR grade, InvitrogenTM, Carlsbad, CA, U.S.A); 0,5µl of forward primer and 0,5µl of 
reverse primer (both at 25pmol/µl); and 0,2µl of Taq DNA recombinant polymerase (MBI Fermentas, 
Vilnius, Lituânia; 5 U/µl). The final volume was obtained by adding 18,8µl of distilled water (B 
Braun®). 
The PCR protocol consisted of an initial denaturation step at 94ºC for 5 minutes!followed by 35 cycles 
of denaturation at 94ºC for a minute, annealing at 65ºC (exons 2, 4 and 13/14), 64ºC (exons 3 and 17), 
62ºC (exons 5/6, 11/12, 18/19, 20 and 21-23), 60ºC (exons 7/8 and 16), 59ºC (exons 9/10), 57ºC (exon 
15) for another minute, extension at 72ºC also for a minute and a final extension at 72ºC for 10 
minutes. 
To confirm the effectiveness of the amplification reaction, the PCR products were checked by 
capillary electrophoresis in a QIAxcel® System (Quiagen, Hilden, Germany). 
The products obtained with the PCR reaction were then purified with Agencourt AMPure XP 
(Beckman Coulter, Brea, CA, U.S.A.) according to the manufacturer’s instructions. 
Finally, the purified PCR products were automatically sequenced in an ABI PRISM® Genetic 
Analyzer, using the fluorescence-based BigDye® Terminator sequencing standard. 
All NOTCH3 sequence variants identified in the original DNA analyses were confirmed in a second 
PCR amplification of the corresponding exon. 
 
 RESULTS 
From the total of 11 patients with previously diagnosed CADASIL and identified NOTCH3 mutation 8 
were index cases and 3 were relatives. Every patient had clinical manifestations of the disease at the 
time of observation with the mean age at onset being 43,3 ± 18,9 (mean ± SD). The mean age at 
observation was 53,3 ± 14,1 (mean ± SD; range 43,8 – 62,8). Three of the 11 patients were males and 8 
were females and the mean age at observation was respectively 51,7 ± 23,4 and 53,9 ± 11,3. Such 
differences between sexes were not statistically significant and no difference between sexes was found 
in what concerns to age at onset.  
Six of the 11 patiens had mutations in the exon 11, two of them had mutations in the exon 4, two had a 
mutation located in exon 8 and 1 had a mutation located in exon 20 (table2). 
The clinical manifestations studied are also described in table 2 in order to allow the establishment of a 
relation between them and the mutation found.  Migraine without aura was the most frequently 
observed (5/11) The second most frequent finding was depression (3/11) followed by both TIA’s (2/11) 
and stroke (2/11).  
Only 4 patients had done MRI (table 3) and the most frequent findings were areas of hyperintensity 
both in periventricular areas (3/4) and centrum semiovale  (3/4). From the 3 patients with hyperintensiy 
in periventricular areas, 2 were found to have the p. R558C mutation and the other, the p. C1009Y 
mutation. The exact same finding was observed in what concerns the 3 patients with hyperintensity in 
the centrum semiovale. 
Familiar history of symptoms was reported in 7 patients (table 4). The most frequent familiar finding 
was early onset stroke (5/11). The other more frequent findings were dementia (4/11), followed by 
migraine without aura (2/11) and depression (2/11). No patient had familiar history of TIA’s or 
migraine with aura. The Odds ratio (OR) presented in the bottom of the table 3 were calculated in order 
to understand if is there a relation between familiar history and patient clinical manifestations. Familiar 
history does not seem to be related to our patients’ symptoms however, none of these results were 
found to be statistically significant. 
The presence of arterial hypertension, diabetes mellitus, dyslipidemia and the use of tobacco were used 
to study cardiovascular risk factors (CVRF). Six out of the 11 patients had some sort of cardiovascular 
risk factor. Dyslipidemia was the most frequent CVRF (4/11). Two patients had arterial hypertension, 
and other 2 had smoking history. None of all 11 patients had diabetes mellitus. 
In table 5 it is shown the relation between CVRF and clinical manifestations. Migraine without aura 
risk was increased in patients with arterial hypertension (odds ratio [OR] = 1,25; 95% CI, 0,04 to 
36,22; P<0,05) and in patients with Diabetes Mellitus (odds ratio [OR] = 4,0; 95% CI, 0,27 to 60,32; 
P<0,05). Depression risk was increased in patients with Diabetes Mellitus as well (odds ratio [OR] = 
1,2; 95% CI, 0,07 to 19,63; P<0,05). However, once again this results are non statistically significant 
due the valor of 95% CI including 1. 
No other CVRF were associated with any clinical manifestation of the disease, including dementia, 
migraine with aura, early onset stroke or TIA. 
 
DISCUSSION 
This study focused on the clinical manifestations of a Portuguese sample of CADASIL patients 
followed in HSJ by evaluating the presence of major clinical manifestations reported on the disease. 
We identified 6 different mutations in 4 exons with exon 11 being the most frequently affected. Eight 
out of the 11 patients studied had mutations either on exon 11 or 4 which are reported to be 2 of the 
most frequent exons affected in patients with CADASIL[23] and in a previous study, were showed to 
be the most frequent mutation sites in the Portuguese population[24]. In that study, more than 90% of 
the patients had mutations either on exon 4 or 11. In our study, the percentage was 73% however we 
believe that using a larger sample, we would obtain similar values to that found by Ferreira et al..We 
were not able to establish a relation between clinical manifestations and the different NOTCH3 
mutations found. This absence of any association might be related to the limited number of patients 
studied which resulted in low statistical robustness. However, even though some studies 
describe phenotype-genotype correlations, Singhal et al. reported that the genotype cannot be used to 
predict the phenotype in individuals with CADASIL[27] which makes us think that only with a very 
larger sample would we have obtained satisfactory results. 
The mean age at onset of the symptoms was identical to the reported in other papers[8].  
Several studies already reported the major clinical manifestations of CADASIL [6,9-12] as early onset 
recurrent subcortical ischemic events, cognitive decline, psychiatric disturbance and migraine with aura 
[9,10], and based on those studies we questioned our sample whether they had experienced said 
symptomsThe most frequent clinical manifestation amongst our sample was migraine without aura. 
This finding can be expected in CADASIL patients since most cases present with migraine, mostly 
with aura though. Moreover, Desmond et al. reported that in a significant number of cases, migraine 
with aura was the presenting symptom [28]. Nonetheless, Dichgans reported that despite the high 
prevalence of patients with migraine with aura, most individuals also had experienced episodes without 
aura[9]. This leads us to question whether the presence of migraine might or not be related to the 
disease. Although migraine can be expected in patients with CADASIL, due to the reduced number of 
patients studied we cannot be sure whether this symptom is caused by the disease. Depression is not 
reported as usual at onset of CADASIL, instead, it appears to be more likely to occur later in the course 
of the disease as observed by Desmond et al [28]. Also, similarly to our study, where depression was 
the second most frequent symptom, Bianchi et al. reported a high frequency of psychiatric symptoms 
like depression. The other two most frequent findings were TIA’s and early onset stroke which are 
consistent with the studies of Dichgans et al. in suggesting ischemic deficits as one of the most frequent 
findings in patients with CADASIL[9]. The similarity between our findings and the previously reported 
clinical manifestations suggest that there is none particular difference between the Portuguese 
population and any other given cohort. Thought further studies with wider samples are recommended 
in order to extrapolate our findings to the Portuguese CADASIL patients population. 
MRI lesions can be highly characteristic of the disease and are thought to appear before any clinical 
manifestation, unfortunately we were only able to evaluate 4 patients. [15]. The most frequent findings 
were areas of hyperintensity in the periventricular caps and in the centrum semiovale. Hervé and 
Chabriat also reported these findings in patients under 40 years,  leading us to believe such 
abnormalities are, in fact, due to the disease[8]. In addition, a recent report by Choi, JC reports initial 
MRI lesions in the periventricular areas to subsequently extend into basal ganglia, thalamus and 
brainstem which we found to be the second most frequent locations for MRI abnormalities in our 
patients [4]. Once again, and with more emphasis in what concerns to the MRI, we believe a larger 
sample would be beneficial since the imaging in CADASIL can be rather unique and we only studied 4 
patients in 11 possible. Nonetheless, we were capable of, even in such a small sample, encounter the 
typical findings expected in this disease. 
As far as we are concerned, no familiar history of symptomatic relatives could be associated to any 
kind of symptom in our patients. But it seems to be clear that a well-made family history questionnaire 
is crucial for the clinical diagnosis of CADASIL as are dialing with and autosomal dominant disease 
and even in a small sample like ours most of the patients (7/11) had any kind familiar history of 
symptoms.  The distinction between first or other degree relatives was not assessed in the questionnaire 
which could be important to future investigation results. 
Concerning the relation between clinical manifestations and CVRF the sample size issue was again 
important and probably due to it no statistically significant results were found as well. The risk of 
migraine with aura was higher both in patients with arterial hypertension or patients with diabetes 
mellitus. Also, the risk of depression appeared to be elevated in patients with diabetes mellitus. Abid-
Samii et al. suggested CVRF as being capable of modulating the disease and increase the disease 
severity. In that study, no relevant role was found concerning the relation between CVRF and migraine 
or depression however in a study by Singhal, an association between migraine and high serum levels of 
homocysteine in patients with CADASIL has been described although not being known the mechanism 
by which the elevated levels of homocysteine could predispose to this symptom[27]. One problem 
associated with the study of CVRF was the lack of specific criteria to define different levels of arterial 
hypertension, as well as dyslipidemia. Also, there were no distinction between currently and ex-
smokers. 
 
CONCLUSIONS 
The present study permitted us to conclude that there are very significant similarities between 
portuguese and non-portuguese patients diagnosed with CADASIL despite the different clustering 
regions of the NOTCH3 mutations. The mean age at onset of the symptoms in Portuguese patients were 
similar to earlier studies in different populations and that despite the difficulties in creating a statistical 
significant study of the major symptoms in CADASIL, our findings were highly identical to those of 
other studies.  
The MRI abnormalities observed can be interpreted as confirmation of such similarities between 
portuguese and non portuguese CADASIL patients.  
We could not create any significant phenotype-genotype relation and no significant relation was found 
between clinical manifestation and familiar history or clinical manifestation and CVRF. Nonetheless, 
we consider that the sample size may have precluded further detailed analysis and believe that a larger 
number of patients should be studied in order for the results to be better correlated and explored. 
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Figure 1: Quetionnaire used created by the Department of Genetics and used to collect cinical data 
form our patients 
  
Table 1: Primers used in the amplification PCR reaction 
Primer&
code! Primer!oligonucleotide!sequence! Primer!coordinatesa!CAD!2F! 5’9atgcagctgttgcctggtgga93’! 83039!8323!CAD!2R! 5’9ggttgcccaagccacacacat93’! 86199!8599!CAD!3F! 5’9tgtgctgcccaaccaagcca93’! 13430913449!CAD!3R! 5’9actgaccacacccccgacta93’! 136539!13634 CAD!4F! 5’9tagtcgggggtgtggtcagt!93’! 136349!13653!CAD!4R! 5’9cctctgactctcctgagtag93’! 140539!14034!CAD!5F! 5’9ctactcaggagagtcagagg93’! 140349!14053!CAD!6R! 5’9tgccctcactaaaaaccatc93’! 146109!14591!CAD!7F! 5’9acaatactcaaggggtgtgg93’! 164799!16498!CAD!8R! 5’9acccacttacaccccattct93’! 170909!17071!CAD!9F! 5’9tgacagtccagcctgtggctga93’! 174669!17487!CAD!10R! 5’9ggctccacacgtagccttatgt93’! 182809!18259!CAD!11F! 5’9tgatgggcagggcctcagat93’! 185399!18558!CAD!12R! 5’9tcgttggacaagagtctgca93’! 192089!19189!CAD!13F! 5’9gcacaagagctgatgcgttatg93’! 201699!20190!CAD!14R! 5’9gctcctggagggaaatgattga93’! 208519!20830!CAD!15F! 5’9ctttcaatcatttccctccag93’! 208279!20847!CAD!15R! 5’9aggctgcatatcagtgtcca93’! 212359!21216!CAD!16F! 5’9cgaatgacagcacggcttat!93’! 214069!21425!CAD!16R! 5’9caggcacacagttcaagctt93’! 217579!21738!CAD!17F! 5’9aggcatatcccagtcagact93’! 241109!24129!CAD!17R! 5’9atcagtcatcagagtccgca93’! 245389!24519!CAD!18F! 5’9ccccattcggctcacacta93’! 253859!25367!CAD!19R! 5’9agggacctgattggcttctg93’! 246659!24684!CAD!20F! 5’9ggactcattccaccaaggatgt93’! 256279!25648!CAD!20R! 5’9caagccacacagaaatgtgtgc93’! 259909!25969!CAD!21F! 5’9tactggtagtgcgctgaaca93’! 263609!26379!CAD!23R! 5’9gattacaggtgtgagcta93’! 273279!27310!
 
  
Table 2: Clinical Manifestations and NOTCH3 mutations 
Patient' Exon' Mutation'
Clinical'Manifestations'
Early'onset'
stroke' TIA' Migraine'w/'aura'
Migraine'
w/out'aura' Depression' Dementia' Other'
1' 11' R558C' D' x' D' D' D' D' D'
2' 11' R558C' D' D' D' D' x' D' D'
3' 11' R558C' D' D' D' x' x' D' D'
4' 4' R153C' x' D' D' D' D' D' D'
5' 11' R558C' D' D' D' D' D' D' x'
6' 4' C168S' D' D' D' x' D' D' D'
7' 11' R558C' x' D' D' x' D' D' D'
8' 8' G420C' D' D' D' x' D' D' D'
9' 8' G420C' D' D' D' x' D' D' D'
10' 20' C1099Y' D' x' D' D' D' D' D'
11' 11' R607C' D' D' x' D' x' x' D'
 
  
Table 3: Imagiological Findings 
MRI'Findings*'
Patient'1'
(R558C)'
Patient'5'
(R558C)'
Patient'7'
(R558C)'
Patient'10'
(C1099Y)'
Basal'Ganglia' ' x' ' x'
Brainstem' ' x' ' '
Corpus'Callosum' ' x' ' '
External'Capsule' x' ' ' '
Periventricular' x' x' ' x'
Centrum'Semiovale' ' x' x' x'
Thalamus' ' x' ' x'
Frontotemporal'Lobe' ' ' ' '
'' ' ' ' '
Enlarged'periventricular'Spaces' ' ' x' '
* Cerebral structure or location where areas of hyperintensity on T2-weighted, and FLAIR images were 
observed 
  
Table 4: Relations between clinical manifestations and familar history 
Patient'
Familiar'History'
Early'onset'Stroke' TIA' Migraine'w/'aura' Migraine'w/out'aura' Depression' Dementia' Other'
1' X'' D' D' D' D' D' D'
2' D' D' D' D' D' D' D'
3' x' D' D' x' x' x' D'
4' D' D' D' D' D' D' D'
5' D' D' D' D' D' D' D'
6' D' D' D' x' D' x' D'
7' x' D' D' D' D' D' D'
8' D' D' D' D' D' x' D'
9' x' D' D' D' D' D' D'
10' D' D' D' D' D' D' D'
11' x' D' D' D' x' x' x'
Odds'Ratio' 0,80'(0,04'D'17,19)*'
0,06'
(0,00D3,74)*'
0,03'
(0,00D2,09)*'
0,5'
(0,02D14,90)*'
0,13''
(0,002D5,22)*'
0,21''
(0,01D8,28)*'
0,06''
(0,001D2,96)*'
*Values'shown'are'OR's'with'95%'CI's'calculated'to'illustrate'the'relation'between'the'presence'of'a'familiar'symptom'and'the'presence'of'the'
same'symptom'in'patients 
  
Table 5: Relations between cardiovascular risk factors and clinical manifestations 
'' Dementia' Depression' Migraine'w/'aura'
Migraine'
w/out'aura'
Early'onset'
stroke' TIA' Other'
Arterial'
Hypertension'
0,13''
(0,003D5,22)'
0,29''
(0,01D6,91)'
0,13''
(0,003D5,22)'
1,25''
(0,04D36,22)'
0,28''
(0,01D9,23)'
0,13''
(0,003D3,99)'
0,13''
(0,003D5,22)'
Diabetes'Mellitus' 0,34''(0,01D12,48)'
1,2''
(0,07D19,63)'
0,34''
(0,01D12,48)'
4,0''
(0,27D60,32)'
0,8''
(0,03D23,18)'
0,28''
(0,01D9,23)'
0,34''
(0,01D12,48)'
Dyslipidemia' 0,03''(0,00D2,09)'
0,09''
(0,001D5,88)'
0,03''
(0,00D2,09)'
0,21''
(0,003D12,52)'
0,06''
(0,00D3,74)'
0,06''
(0,00D3,74)'
0,03''
(0,00D2,09)'
Smoking'History' 0,13''(0,003D5,22)'
0,28''
(0,01D6,91)'
0,13''
(0,002D5,22)'
0,80''
(0,04'D'17,19)'
0,13''
(0,003D3,99)'
0,28''
(0,01'D'9,23)'
0,13''
(0,003D5,22)'
Other' 0,03''(0,00D2,09)'
0,09''
(0,001D5,88)'
0,09''
(0,001D5,88)'
0,21''
(0,003D12,52)'
0,06''
(0,00D3,74)'
0,06''
(0,00D3,74)'
0,03''
(0,00D2,09)'
Values''shown''are'OR's'with'95%'CI's.'
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